This fact sheet describes the tests used to diagnose prostate cancer and explains what the results may show.

Last updated: July 2016
To be reviewed July 2018

References  

  • Berney DM. The case for modifying the Gleason grading system. BJU Int. 2007;100(4):725–726.
  • Bostwick DG, Meiers I. Atypical small acinar proliferation in the prostate: clinical significance in 2006. Arch Pathol Lab Med. 2006;130(7):952–957.
  • Buskirk SJ, Pinkstaff DM, Petrou SP, Wehle MJ, Broderick GA, Young PR, et al. Acute urinary retention after transperineal template-guided prostate biopsy. Int J Radiat Oncol. 2004 Aug;59(5):1360–6.
  • Cancer Research UK. Prostate cancer incidence statistics [Internet]. 2014 [cited 2014 Sep 16]. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/incidence/#age
  • Cancer Research UK. Prostate cancer incidence statistics: Lifetime risk (2010). 2012.
  • Cao Y, Ma J. Body Mass Index, Prostate Cancer-Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis. Cancer Prev Res (Phila Pa). 2011 Jan 13;4(4):486–501.
  • Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Jama. 1998;279(19):1542–1547.
  • Clouston D, Bolton D. In situ and intraductal epithelial proliferations of prostate: Definitions and treatment implications Part 1: Prostatic intraepithelial neoplasia. BJU Int. 2012;109(s3):22–26.
  • Collin SM, Metcalfe C, Donovan J, Lane JA, Davis M, Neal D, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int. 2008 Jun 6;102(0):1400–6.
  • Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer. 2011 Nov 8;105:S52–73.
  • Eichler K, Wilby J, Hempel S, Myers L, Kleijnen J, University of York, et al. Diagnostic value of systematic prostate biopsy methods in the investigation for prostate cancer: A systematic review. Centre for Reviews and Dissemination (CRD); 2005.
  • Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–252.
  • Froehner M, Buck LM, Koch R, Hakenberg OW, Wirth MP. Derivatives of prostate-specific antigen as predictors of incidental prostate cancer. BJU Int. 2009 Jul;104(1):25–8.
  • Haffner J, Lemaitre L, Puech P, Haber G-P, Leroy X, Jones JS, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011 Oct 1;108(8b):E171–8.
  • Husson O, Mols F, Poll-Franse LV van de. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol. 2010 Sep 24;mdq413.
  • Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003;91(9):789–794.
  • Jones AL, Chinegwundoh F. Update on prostate cancer in black men within the UK. Ecancermedicalscience. 2014;8:455.
  • Kirkham APS, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol. 2006 Dec;50(6):1163–1174; discussion 1175.
  • Laurila M, van der Kwast T, Bubendorf L, di Lollo S, Pihl C-G, Ciatto S, et al. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer. Eur J Cancer. 2010 Nov;46(17):3068–72.
  • Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010. BMC Med. 2015 Dec;13(1).
  • Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013 Dec;64(6):876–92.
  • Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 2012;8:CD007566.
  • Moch H, Cubilla A, Humphrey P, Reuter V, Ulbright T. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and BladderTumours [Internet]. 2016. Available from: http://www.europeanurology.com/article/S0302-2838%2816%2900205-0/abstract/the-2016-who-classification-of-tumours-of-the-urinary-system-and-male-genital-organs-part-b-prostate-and-bladder-tumours
  • Montironi R, Scattoni V, Mazzucchelli R, Lopez-Beltran A, Bostwick DG, Montorsi F. Atypical Foci Suspicious but not Diagnostic of Malignancy in Prostate Needle Biopsies. Eur Urol. 2006 Oct;50(4):666–74.
  • Mottet N, Bellmunt J, Briers E, Bolla M, Cornford P, De Santis M, et al. EAU Guidelines on Prostate Cancer 2016 [Internet]. European Association of Urology; 2016. Available from: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2016.pdf
  • MRI scan - Who can have one? - NHS Choices [Internet]. [cited 2015 Dec 3]. Available from: http://www.nhs.uk/Conditions/MRI-scan/Pages/Who-can-use-it.aspx
  • Murray KS, Bailey J, Zuk K, Lopez-Corona E, Thrasher JB. A prospective study of erectile function after transrectal ultrasonography-guided prostate biopsy. BJU Int. 2015 Aug;116(2):190–5.
  • National Institute for Health and Care Excellence. NICE Clinical Guideline 97: Lower urinary tract symptoms: The management of lower urinary tract symptoms in men [Internet]. 2010. Available from: http://www.nice.org.uk/guidance/cg97/resources/guidance-lower-urinary-tract-symptoms-pdf
  • National Institute for Health and Care Excellence. Prostate Cancer: diagnosis and treatment. Full guideline 175. 2014.
  • National Institute for Health and Care Excellence. Sepsis: recognition, diagnosis and early management. NICE guideline 51. 2016.
  • National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. NICE Guideline 12. June 2015 [Internet]. 2015. Available from: http://www.nice.org.uk/guidance/ng12/evidence/full-guidance-65700685
  • National Institute for Health and Care Excellence. Transperineal template biopsy and mapping of the prostate. 2010.
  • NHS Cancer Screening Programmes. Undertaking a transrectal ultrasound guided biopsy of the prostate. PCRMP Guide No 1. 2006.
  • NHS Choices. Urinary tract infection in adults [Internet]. 2016. Available from: http://www.nhs.uk/conditions/Urinary-tract-infection-adults/Pages/Introduction.aspx
  • Nogueira L, Corradi R, Eastham JA. Other biomarkers for detecting prostate cancer. BJU Int. 2010 Jan;105(2):166–9.
  • Pinkstaff DM, Igel TC, Petrou SP, Broderick GA, Wehle MJ, Young PR. Systematic transperineal ultrasound-guided template biopsy of the prostate: Three-year experience. Urology. 2005 Apr;65(4):735–9.
  • Popiolek M, Rider JR, Andrén O, Andersson S-O, Holmberg L, Adami H-O, et al. Natural History of Early, Localized Prostate Cancer: A Final Report from Three Decades of Follow-up. Eur Urol. 2013;63(3):428–35.
  • Price CP, Allard J, Davies G, Dawnay A, Duffy MJ, France M, et al. Pre-and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem. 2001;38(3):188–216.
  • Prostate Cancer UK. Consensus statements on PSA testing in asymptomatic men in the UK [Internet]. 2016. Available from: www.prostatecanceruk.org/PSAconsensusHP
  • Public Health England. Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing [Internet]. GOV.UK; 2016. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks/prostate-cancer-risk-management-programme-pcrmp-benefits-and-risks-of-psa-testing
  • Public Health England. Prostate cancer risk management programme (PCRMP): PSA test benefits and risks [Internet]. 2016 [cited 2016 May 4]. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks
  • Remzi M, Haese A, Van Poppel H, De La Taille A, Stenzl A, Hennenlotter J, et al. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? BJU Int. 2010 Oct;106(8):1138–42.
  • Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical Activity after Diagnosis and Risk of Prostate Cancer Progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer Res. 2011 May 24;71(11):3889–95. • Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ. 2012;344:d7894.
  • Schilling D, de Reijke T, Tombal B, de la Taille A, Hennenlotter J, Stenzl A. The Prostate Cancer gene 3 assay: indications for use in clinical practice. BJU Int. 2010 Feb;105(4):452–5.
  • Symons JL, Huo A, Yuen CL, Haynes A-M, Matthews J, Sutherland RL, et al. Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int. 2013;112(5):585–593.
  • Trottier G, Boström PJ, Lawrentschuk N, Fleshner NE. Nutraceuticals and prostate cancer prevention: a current review. Nat Rev Urol. 2009 Dec 8;7(1):21–30.
  • Tuncel A, Toprak U, Balci M, Koseoglu E, Aksoy Y, Karademir A, et al. Impact of transrectal prostate needle biopsy on erectile function: Results of power Doppler ultrasonography of the prostate. Kaohsiung J Med Sci. 2014 Apr;30(4):194–9.
  • Van Patten CL, de Boer JG, Tomlinson Guns ES. Diet and Dietary Supplement Intervention Trials for the Prevention of Prostate Cancer Recurrence: A Review of the Randomized Controlled Trial Evidence. J Urol. 2008 Dec;180(6):2314–22.
  • World Cancer Research Fund International. Continuous Update Project report: Diet, Nutrition, Physical Activity and Prostate Cancer [Internet]. 2014. Available from: www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf
  • Zynger DL, Yang X. High-grade prostatic intraepithelial neoplasia of the prostate: the precursor lesion of prostate cancer. Int J Clin Exp Pathol. 2009;2(4):327.

Order printed copies of this publication

Before you order we would like to know who you are, and why you are ordering printed copies.

Download digital versions of this publication